Gadducci A, Ferdeghini M, Cosio S, Annicchiarico C, Fanucchi A, Prontera C, Bianchi R, Genazzani A R
Department of Gynecology and Obstetrics, University of Pisa, Italy.
Anticancer Res. 1998 Jan-Feb;18(1B):537-9.
The pretreatment serum levels of soluble CD44 standard (sCD44st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) were retrospectively measured in 37 patients with untreated cervical cancer and in 36 patients with benign gynecological diseases as controls. Median sCD44-st levels were significantly higher in patients with cervical cancer than in controls (547 ng/ml, range 244-880 ng/ml versus 400.5 ng/ml, range 217-723 ng/ml, p = 0.004), whereas sCD44-v5 and sCD44-v6 concentrations were significantly lower in the former (34 ng/ml, range 0-140 ng/ml versus 44 ng/ml, range 11-109 ng/ml, p = 0.038; and 37 ng/ml, range 1-191 ng/ml versus 52.5 ng/ml, range 11-173 ng/ml, p = 0.007, respectively). sCD44-st, sCD44-v5, and sCD44-v6 levels were not related to FIGO stage and histologic type. Moreover, among patients with stage Ib-IIa cervical cancer, the preoperative levels of these glycoproteins correlated with neither the common prognostic variables nor the clinical outcome. Therefore, the serum assay of sCD44-st, sCD44-v5, and sCD44-v6 seems to have no clinical relevance for the management of patients with cervical cancer.
回顾性检测了37例未经治疗的宫颈癌患者及36例患有良性妇科疾病的对照患者血清中可溶性CD44标准物（sCD44st）、CD44剪接变异体5（sCD44-v5）和CD44剪接变异体6（sCD44-v6）的预处理水平。宫颈癌患者的sCD44-st中位水平显著高于对照组（547 ng/ml，范围244 - 880 ng/ml，而对照组为400.5 ng/ml，范围217 - 723 ng/ml，p = 0.004），而前者的sCD44-v5和sCD44-v6浓度显著较低（分别为34 ng/ml，范围0 - 140 ng/ml，对照组为44 ng/ml，范围11 - 109 ng/ml，p = 0.038；以及37 ng/ml，范围1 - 191 ng/ml，对照组为52.5 ng/ml，范围11 - 173 ng/ml，p = 0.007）。sCD44-st、sCD44-v5和sCD44-v6水平与国际妇产科联盟（FIGO）分期及组织学类型无关。此外，在Ib-IIa期宫颈癌患者中，这些糖蛋白的术前水平与常见的预后变量及临床结局均无相关性。因此，sCD44-st、sCD44-v5和sCD44-v6的血清检测似乎对宫颈癌患者的管理无临床意义。
